<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4142</journal-id>
<journal-title><![CDATA[Revista Costarricense de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. costarric. cardiol]]></abbrev-journal-title>
<issn>1409-4142</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-41422019000100007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cardiotoxicidad de los quimioterapéuticosdiferentes a antraciclinas de la lista oficial de medicamentosde la Caja Costarricense del Seguro Social]]></article-title>
<article-title xml:lang="en"><![CDATA[Cardiotoxicity of chemotherapeutics other than anthracyclines from the official list of medications of the Costa Rican Social Security Fund]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salas Segura]]></surname>
<given-names><![CDATA[Juliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Carvajal]]></surname>
<given-names><![CDATA[José Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital San Juan de Dios  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<numero>1</numero>
<fpage>7</fpage>
<lpage>13</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-41422019000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-41422019000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-41422019000100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La Cardio-oncología es una nueva disciplina que busca enfocarse en el tamizaje, monitoreo y tratamiento de los pacientes con cáncer que presentan enfermedad cardiaca durante o después de recibir tratamiento. Esto debido a que el efecto cardiotóxico asociado a los quimioterapéuticos es ampliamente conocido y respaldado por abundantes estudios clínicos. Sin embargo, no es hasta épocas recientes que en Costa Rica se desarrollaron por primera vez Unidades Cardio-oncológicas, los cuales actualmente se ubican en diversos centros médicos de nuestro sistema de salud público. A continuación, se presenta un resumen de las manifestaciones clínicas de las diversas terapias oncológicas diferentes a las antraciclinas que tenemos a disposición en la Caja Costarricense del Seguro Social (CCSS).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Cardio-oncology is a new discipline that looks to focus on the screening, monitoring and treatment of patients withcancer that show up with heart disease during and after their treatment. This is due to the fact that the cardiotoxic effectsassociated to chemotherapeutics is widely known and backed up with abundant clinical trials. Nevertheless, it is not untilrecently that in Costa Rica the Cardio-oncologic Units were created for the first time, which now can be found in multiplemedical centers of our public health system. Up next, we present a summary of the clinical manifestations of the diversenon-anthracycline oncologic therapies that are available in the &#8220;Caja Costarricense del Seguro Social&#8221;.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="es"><![CDATA[Cardiotoxicidad]]></kwd>
<kwd lng="es"><![CDATA[Cardio-oncología]]></kwd>
<kwd lng="en"><![CDATA[Chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[Cardiotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Cardio-oncology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adão]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[De Keulenaer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Leite-Moreira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brás-Silva]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention]]></article-title>
<source><![CDATA[RevPort Cardiol]]></source>
<year>2013</year>
<volume>32</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>395-409</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenneman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sawyer]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardio-Oncology: An Update on Cardiotoxicityof Cancer-Related Treatment]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2016</year>
<volume>118</volume>
<page-range>1008-20</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Fernández]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Thavendiranathan]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas técnicas deimagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos]]></article-title>
<source><![CDATA[Rev Esp Cardiol.]]></source>
<year>2017</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>487-95</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plana]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Galderisi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barac]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expert consensus for multimodalityimaging evaluation of adult patients during and after cáncer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr.]]></source>
<year>2014</year>
<volume>27</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>911-39</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tajiri]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Aonuma]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Sekine]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardio-oncology: a multidisciplinaryapproach for detection, prevention and management of cardiac dysfunction in cancer patients]]></article-title>
<source><![CDATA[Jpn J Clin Oncol]]></source>
<year>2017</year>
<volume>47</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>678-82</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plana]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Galderisi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barac]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expert consensus for multimodalityimaging evaluation of adult patients during and after cáncer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr.]]></source>
<year>2014</year>
<volume>27</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>911-39</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gottdiener]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Appelbaum]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrans]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Deisseroth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegler]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity associated with high-dose cyclophosphamide therapy]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1981</year>
<volume>141</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>758</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Appelbaum]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Strauchen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Graw Jr]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Savage]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrans]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Herzig]]></surname>
<given-names><![CDATA[GP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1976</year>
<volume>1</volume>
<numero>7950</numero>
<issue>7950</issue>
<page-range>58</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quezado]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Cunnion]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Reda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bryant]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ognibene]]></surname>
<given-names><![CDATA[FP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1993</year>
<volume>118</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kandylis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vassilomanolakis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tsoussis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Efremidis]]></surname>
<given-names><![CDATA[AP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ifosfamidecardiotoxicity in humans.]]></article-title>
<source><![CDATA[Cancer Chemother Pharmacol.]]></source>
<year>1989</year>
<volume>24</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>395</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huddart]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shahidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Horwich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coward]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dearnaley]]></surname>
<given-names><![CDATA[DP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease as a long-term complication oftreatment for testicular cancer.]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2003</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1513</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fung]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sesso]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multi-Institutional Assessment ofAdverse Health Outcomes Among North American Testicular CancerSurvivors After Modern Cisplatin-Based Chemotherapy.]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>2017</year>
<volume>35</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1211</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of chemotherapy on the heart]]></article-title>
<source><![CDATA[Cancer and theHeart, Kapoor AS (Ed)]]></source>
<year>1986</year>
<page-range>223</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer Verlag]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grem]]></surname>
<given-names><![CDATA[JL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[5-Fluorouracil: forty-plus and still ticking. A review ofits preclinical and clinical development]]></article-title>
<source><![CDATA[Invest New Drugs.]]></source>
<year>2000</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>299-313</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saif]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[AR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluoropyrimidine-associated cardiotoxicity:revisited]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2009</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Hasbak]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mortensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sørensen]]></surname>
<given-names><![CDATA[JB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluorouracil inducesmyocardial ischemia with increases of plasma brain natriuretic peptideand lactic acid but without dysfunction of left ventricle]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2010</year>
<volume>28</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>5280</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosmas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kallistratos]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Kopterides]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity offluoropyrimidines in different schedules of administration: aprospective study]]></article-title>
<source><![CDATA[J Cancer Res Clin Oncol]]></source>
<year>2008</year>
<volume>134</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-82</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Araki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ligo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of monitoringserum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer.]]></article-title>
<source><![CDATA[Cancer Chemother Pharmacol.]]></source>
<year>1990</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>352-4</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Forni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Malet-Martino]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Jaillais]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity of highdosecontinuous infusion fluorouracil: a prospective clinical study.]]></article-title>
<source><![CDATA[JClin Oncol]]></source>
<year>1992</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1795</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kettunen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Huikuri]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Oikarinen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Takkunen]]></surname>
<given-names><![CDATA[JT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methotrexate-linkedventricular arrhythmias]]></article-title>
<source><![CDATA[Acta Derm Venereol.]]></source>
<year>1995</year>
<volume>75</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>391</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez-Verdia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Angulo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hardwicke]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Nugent]]></surname>
<given-names><![CDATA[KM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute cardiactoxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2005</year>
<volume>25</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1271</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermans]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Straetmans]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Michaux]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrant]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pericarditis inducedby high-dose cytosine arabinoside chemotherapy]]></article-title>
<source><![CDATA[Ann Hematol]]></source>
<year>1997</year>
<volume>75</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>55</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keefe]]></surname>
<given-names><![CDATA[DL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastuzumab-associated cardiotoxicity.]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2002</year>
<volume>95</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1592</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Blackwell]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Independent adjudicationof symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer TreatmentGroup N9831 clinical trials]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2010</year>
<volume>28</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>3416</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Millward]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Bandarenko]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Stagg]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Afenyi-Annan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hay]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Brecher]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiogenic shock complicates successful treatmentof refractory thrombotic thrombocytopenia purpura with rituximab.]]></article-title>
<source><![CDATA[Transfusion]]></source>
<year>2005</year>
<volume>45</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1481</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cersosimo]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoclonal antibodies in the treatment of cancer, Part 1.]]></article-title>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2003</year>
<volume>60</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1531</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cargill]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Boyter]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Lipworth]]></surname>
<given-names><![CDATA[BJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reversible myocardial ischaemiafollowing vincristine containing chemotherapy.]]></article-title>
<source><![CDATA[Respir Med]]></source>
<year>1994</year>
<volume>88</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>709</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yancey]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Talpaz]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vindesine-associated angina and ECG changes.]]></article-title>
<source><![CDATA[Cancer Treat Rep.]]></source>
<year>1982</year>
<volume>66</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>587</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gehl]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boesgaard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paaske]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vittrup Jensen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dombernowsky]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>1996</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>687</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dorr]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lyss]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoadjuvant and adjuvantchemotherapy with doxorubicin and docetaxel in locally advancedbreast cancer]]></article-title>
<source><![CDATA[Clin Breast Cancer]]></source>
<year>2004</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>377</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fossella]]></surname>
<given-names><![CDATA[FV]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase II study of docetaxelfor recurrent or metastatic non-small-cell lung cancer.]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>1994</year>
<volume>12</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1238</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verweij]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Funke-Küpper]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Teule]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pinedo]]></surname>
<given-names><![CDATA[HM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective studyon the dose dependency of cardiotoxicity induced by mitomycin C.]]></article-title>
<source><![CDATA[Med Oncol Tumor Pharmacother]]></source>
<year>1988</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>159</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ravry]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity of mitomycin C in man and animals]]></article-title>
<source><![CDATA[CancerTreat Rep.]]></source>
<year>1979</year>
<volume>63</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>555</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartzberg]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Kris]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute chest painsyndrome during bleomycin infusions.]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1987</year>
<volume>59</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1582</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vogelzang]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Frenning]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[BJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary artery diseaseafter treatment with bleomycin and vinblastine.]]></article-title>
<source><![CDATA[Cancer Treat Rep]]></source>
<year>1980</year>
<volume>64</volume>
<numero>10-11</numero>
<issue>10-11</issue>
<page-range>1159</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schecter]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[RA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial infarction in a 27-yearoldwoman: possible complication of treatment with VP-16-213 (NSC-141540), mediastinal irradiation, or both.]]></article-title>
<source><![CDATA[Cancer Chemother Rep.]]></source>
<year>1975</year>
<volume>59</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>887</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shimada]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vasospastic angina after chemotherapy withcarboplatin and etoposide in a patient with lung cancer.]]></article-title>
<source><![CDATA[Jpn Circ J]]></source>
<year>1996</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>185</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerkelä]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grazette]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yacobi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity of the cáncer therapeutic agent imatinib mesylate.]]></article-title>
<source><![CDATA[Nat Med.]]></source>
<year>2006</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>908</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atallah]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Durand]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Congestive heartfailure is a rare event in patients receiving imatinib therapy.]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2007</year>
<volume>110</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1233</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2009 focused updateincorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with theInternational Society for Heart and Lung Transplantation.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>119</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>391</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network (NCCN).</collab>
<source><![CDATA[NCCN Clinicalpractice guidelines in oncology.]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="">
<collab>Caja Costarricense de Seguro Social</collab>
<source><![CDATA[Lista oficial de medicamentos]]></source>
<year>2013</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
